Skip to main content

Evelo Biosciences, Inc.

EVLODelisted Dec 27, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001694665

Evelo Biosciences, Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Nov 8, 2023; 29 institutions reported holding it in 13F filings for Q3 2023, worth $52.0M in total; no superinvestor held it.

Holders of 5% or more of EVLO

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Evelo Biosciences, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Evelo Biosciences, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

22 Schedule 13D and 13G filings on Evelo Biosciences, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on EVLO
Filed (ET)FilerFormStakeChangeEvent dateFiling
Dec 11, 2023FMR LLC13G/AOld format–––SEC
Nov 13, 2023FMR LLC13G/AOld format–––SEC
Aug 10, 2023FMR LLC13GOld format–––SEC
Jul 21, 20233:46 PM ETHorizon Technology Finance Corp13GOld format–New–SEC
Jul 21, 2023HarbourVest Partners L.P.13GOld format–––SEC
Jul 13, 2023Flagship Ventures Fund V, L.P.13D/AOld format–––SEC
Jul 10, 2023FMR LLC13G/AOld format–––SEC
Jun 12, 2023FMR LLC13G/AOld format–––SEC
Feb 21, 2023Dnca Finance13D/AOld format–––SEC
Feb 14, 2023HarbourVest Partners L.P.13G/AOld format–––SEC
Feb 9, 2023FMR LLC13G/AOld format–––SEC
Feb 2, 2023Credit Suisse AG13G/AOld format–––SEC
Nov 21, 2022Dnca Finance13D/AOld format–––SEC
Aug 23, 2022Dnca Finance13D/AOld format–––SEC
Jun 1, 2022Flagship Ventures Fund V, L.P.13D/AOld format–––SEC
Feb 14, 2022Credit Suisse AG13G/AOld format–––SEC
Feb 9, 2022FMR LLC13G/AOld format–––SEC
Dec 28, 2021Dnca Finance13DOld format–New–SEC
Feb 16, 2021HarbourVest Partners L.P.13G/AOld format–––SEC
Feb 12, 2021Credit Suisse AG13GOld format–New–SEC
Feb 8, 2021FMR LLC13G/AOld format–––SEC
Feb 4, 2021Flagship Ventures Fund V, L.P.13D/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Evelo Biosciences, Inc. shares.

No Form 144 notices for Evelo Biosciences, Inc. are on file.